GlassScriptPhysician profile
John W Baker
NPI 1003801796
$6,942.14
in general payments reported to CMS, 2019-2025
30 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $223 · 2021: $790 · 2022: $1,379 · 2023: $1,384 · 2024: $1,246 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,632 · Travel and Lodging: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,632.49 |
| Travel and Lodging | $456.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,648.50 | 2019-2025 | Avvigo Guidance System, Watchman Flx, General - Therapies |
| Abiomed | $1,132.86 | 2020-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $612.57 | 2021-2025 | Leqvio |
| Amgen INC. | $549.12 | 2019-2024 | Repatha |
| Teva Pharmaceuticals USA, INC. | $372.82 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $322.52 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $294.25 | 2022-2025 | Amvuttra, Onpattro |
| Atricure, INC. | $284.15 | 2022-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Astrazeneca Pharmaceuticals LP | $229.76 | 2019-2024 | Andexxa, Farxiga |
| Pfizer INC. | $205.23 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $181.95 | 2021-2023 | Verquvo, Belsomra |
| Shockwave Medical, INC | $173.23 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Daxor Corporation | $146.40 | 2022-2023 | Bva-100 |
| Janssen Pharmaceuticals, INC | $134.12 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.32 | 2021-2025 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $105.87 | 2022-2025 | Camzyos |
| Teleflex LLC | $97.23 | 2024 | Manta |
| Irhythm Technologies, INC. | $50.31 | 2019-2022 | |
| Chiesi USA, INC. | $46.17 | 2022-2023 | Cleviprex, Kengreal |
| Nuwellis, INC. | $45.27 | 2022-2023 | Aquadex Smartflow Console |
| Philips North America LLC | $37.99 | 2024 | (Ck4) Mcot |
| Abbott Laboratories | $28.97 | 2022 | |
| Heartflow, INC. | $25.31 | 2023 | Ffrct |
| Inspire Medical Systems, INC. | $21.08 | 2025 | Inspire |
| Novo Nordisk INC | $19.10 | 2022 | |
| Vital Connect, INC | $15.85 | 2023 | Vitalpatch Rtm |
| G Medical Diagnostic Services, INC. | $14.92 | 2019 | |
| Scpharmaceuticals INC. | $14.25 | 2024 | |
| Siemens Medical Solutions USA, INC. | $13.02 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.